Silo Pharma (SILO) announced that IP Australia has granted patent number 2020271839 to Silo’s research and licensing partner Columbia University for the invention titled “Prophylactic efficacy of serotonin 4 receptor agonists against stress” exclusively licensed to Silo by Columbia University. The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder, originally developed by Columbia University.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILO:
- Psychedelic: NRx Pharmaceuticals reports Q2 earnings
- Silo Pharma announces results for 7-day large animal safety study of SPC-15
- Silo Pharma Launches Cryptocurrency Advisory Board
- Silo Pharma appoints Corwin Yu to launch crypto treasury platform
- Silo Pharma Acquires Digital Assets from MAVS Holdings